Alpha 2.0
Login Register
» Articles » PMID: 29669231

Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2018 Apr 19
PMID 29669231
Citations 4
Authors
Joseph M Connors
John A Radford
Affiliations
Soon will be listed here.
Citing Articles

Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.

Arabloo J, Azari S, Gorji H, Rezapour A, Alipour V, Ehsanzadeh S Eur J Clin Pharmacol. 2023; 79(11):1443-1452.

PMID: 37656182 DOI: 10.1007/s00228-023-03557-6.

Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.

Andre M, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M Cancer Med. 2020; 9(18):6565-6575.

PMID: 32710498 PMC: 7520354. DOI: 10.1002/cam4.3298.

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Lees C, Keane C, Gandhi M, Gunawardana J Br J Haematol. 2019; 185(1):25-41.

PMID: 30740662 PMC: 6594147. DOI: 10.1111/bjh.15778.

ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale M, Oki Y, Turturro F, Fayad L, Bartlett N Haematologica. 2018; 104(2):e65-e67.

PMID: 30190343 PMC: 6355491. DOI: 10.3324/haematol.2018.199844.